Participated · Series C · Jul 2026

Ratio Therapeutics is a clinical-stage pharmaceutical company that systematically engineers radiopharmaceuticals using its Trillium pharmacokinetic tuning technology and Macropa chelator platform. Its lead program, [Ac-225]RTX-2358, is in the ATLAS Phase 1/2 trial, and the broader pipeline includes a next-generation GRPR program, additional mono- and bispecific radioligand therapies, and imaging assets. The company has demonstrated external validation through partnered programs, including a collaboration with Novartis on an SSTR2 radioligand therapy. Ratio operates a hybrid manufacturing model with a vertically integrated manufacturing site in Utah, external partners, and diversified isotope supply. Financially, the company recently closed a $70 million Series C that brings total capital raised to over $240 million. Planned near-term activities include advancing the ATLAS trial, filing its fifth IND, moving the next-generation RLT into the clinic, expanding target indications, and scaling manufacturing to support future commercial demand.

Participated · Series A · Jun 2026

Beeline Medicines is a clinical-stage biotechnology company building a focused pipeline of precision therapies rooted in validated biology. Its lead candidate, afimetoran, is a once-daily oral small molecule that targets toll-like receptors 7 and 8 (TLR7/8). Afimetoran has completed a Phase 1b trial in cutaneous lupus erythematosus and is currently in a Phase 2 study with a readout expected by year-end. The company plans to initiate a pivotal lupus trial following the Phase 2 results. Beeline emerged from stealth concurrent with announcing a $300M Series A financing led by Bain Capital. The company emphasizes durable, meaningful outcomes for patients with significant unmet needs and has assembled a leadership team that includes CEO Saqib Islam, COO and President Badreddin Edris, and CMO Nathalie Franchimont.

Participated · Series B · Jan 2026

Precede Biosciences is a precision diagnostics and data company that has built a proprietary, automated assay capable of extracting high-resolution, genome-wide transcriptional information from a single blood draw. The platform integrates this assay with advanced machine-learning analytics, enabling researchers and clinicians to profile target expression and pathway activity—critical biomarkers for drug-, radio- and immune-conjugates and other targeted therapies. By providing a multiplex, minimally invasive alternative to tissue biopsies, the company aims to accelerate drug development and ensure patients receive therapies precisely matched to their disease biology. Current commercial traction is described as “rapidly growing,” driven by partnerships with developers of next-generation precision medicines. The fresh financing brings Precede Bio’s total new capital to $83.5 million, giving the company resources to scale its platform and meet rising demand. An expanded investor base with deep diagnostics-commercialization expertise is expected to support health-system adoption and long-term growth.

Participated · Series A · Jul 2025

Dispatch Bio is developing the Flare platform, which uses a viral vector to deliver a novel, universal antigen (Flare) to target tumor cells and neutralize the immune-suppressive tumor environment. The platform is engineered to enable the immune system to identify and eliminate solid tumor cells while sparing healthy tissue. The company announced a total of $216 million in funding, including a recently closed Series A. Dispatch was founded in 2022 out of a collaboration with the Parker Institute for Cancer Immunotherapy (PICI) and leverages technologies from the labs of Andy Minn, Carl June, Chris Garcia, and Kole Roybal. Leadership includes CEO Sabah Oney and a board and scientific advisory team composed of academic and industry figures. The funding will be used primarily to advance Dispatch’s therapeutic candidates into first-in-human clinical studies, with the first program expected to enter the clinic in 2026.

Participated · Series C · Jan 2025

Be Bio pioneers Engineered B Cell Medicines (BCMs), a platform that programs primary human B cells to produce therapeutic proteins continuously and durably. Its lead programs, BE-101 (Factor IX for hemophilia B) and BE-102 (alkaline phosphatase for hypophosphatasia), are built on this BCM platform and designed to be titratable and re-dosable without preconditioning. BE-101 has an FDA-cleared IND (May 2024), Fast Track designation (September 2024), and is being evaluated in the Phase 1/2 BeCoMe-9 trial to generate clinical proof-of-concept. BE-102 has been selected as a development candidate and is being advanced toward the clinic. The company says proceeds from the Series C will advance BE-101 through proof-of-concept and move BE-102 into clinical development. Be Bio was founded in October 2020 and is based in Cambridge, Mass. Be Biopharma develops engineered B Cell Medicines (BCMs) to improve outcomes for patients with Hemophilia B, other genetic diseases, cancer, and other serious conditions. Its lead program, BE-101, is engineered to insert the human Factor IX (FIX) gene into primary human B cells to enable continuous expression of active FIX. BE-101 aims to deliver sustained therapeutic FIX activity with a single infusion, with the flexibility to be titrated or re-dosed and without the need for preconditioning. The US FDA cleared the BE-101 IND in May 2024 and granted Fast Track designation in September 2024. The company has initiated the Phase 1/2 BeCoMe-9 trial and plans to use the new funding to achieve clinical proof of concept for BE-101 and to advance BE-102. Be Biopharma is led by CEO Joanne Smith-Farrell and is based in Cambridge, MA. Be Biopharma develops Engineered B Cell Medicines (BeCM), operating autologous and allogeneic B‑cell therapy platforms. The company is advancing a broad pipeline initially focused on rare disease and cancer. As it develops its platform, Be Biopharma plans to expand into infectious disease, neurological conditions and autoimmune disease. It closed a $130M financing to support platform advancement and to progress pipeline candidates toward the clinic, bringing total investment to over $180M. Founded in October 2020 and based in Cambridge, MA, the company was launched by Longwood Fund and B‑cell engineering pioneers David Rawlings and Richard James, and is led by CEO Joanne Smith‑Farrell. Be Biopharma develops engineered B cells as a new category of medicines, using the human body's native protein factories to produce therapeutic proteins. The company aims to precisely engineer B cells to exploit their high protein production, selective tissue targeting, and potentially long programmable lifetimes. Be Bio intends its medicines to be durable, re-dosable, and administered without toxic conditioning, opening avenues to treat cancer, autoimmune diseases, monogenic disorders, and enhance responses to infectious pathogens. The platform builds on pioneering work by David Rawlings and Richard James at Seattle Children’s Research Institute. Leadership and scientific founders include Longwood Fund, David Rawlings, Richard James, David Steinberg (CEO and co-founder), Aleks Radovic-Moreno, and Lea Hachigian. The company is based in Cambridge, Mass.